Nattokinase: Conditional Blood Pressure Relief

[1]
Jensen GS, Lenninger M, Ero MP, Benson KF. Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial. Integr Blood Press Control. 2016;9:95-104. Published 2016 Oct 13. doi:10.2147/IBPC.S99553

[2] Kim JY, Gum SN, Paik JK, et al. Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertens Res. 2008;31(8):1583-1588. doi:10.1291/hypres.31.1583

[3] Nattokinase atherothrombotic prevention study: a randomized controlled trial
Hodis HN, Mack WJ, Meiselman HJ, Kalra V, Liebman H, Hwang‐Levine J, Dustin L, Kono N, Mert M, Wenby RB, Huesca E, Rochanda L, Li Y, Yan M, St John JA, Whitfield L
Clinical hemorheology and microcirculation, 2021, 78(4), 339‐353 | added to CENTRAL: 31 May 2021 | 2021 Issue 05
doi.org/10.3233/CH-211147